These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 21139151

  • 41. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
    Hart CW, Joanis C, Hartmann M, Milford C, Smit J, Beksinska M, Rambally-Greener L, Pienaar J, Mabude Z, Butterworth GAM, Sokal D, Jenkins D.
    Eur J Contracept Reprod Health Care; 2019 Oct; 24(5):390-398. PubMed ID: 31517545
    [Abstract] [Full Text] [Related]

  • 42. To tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa.
    Kelly CA, Friedland BA, Morar NS, Katzen LL, Ramjee G, Mokgatle MM, Ahmed K.
    Cult Health Sex; 2015 Oct; 17(8):1004-20. PubMed ID: 25913101
    [Abstract] [Full Text] [Related]

  • 43. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.
    Whitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert JH, Mock PA, Siraprapasiri T, Friedland BA, Kilmarx PH, Markowitz LE.
    PLoS One; 2011 Oct; 6(9):e14831. PubMed ID: 21915249
    [Abstract] [Full Text] [Related]

  • 44. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG, Lanham M, Wilcher R, Gafos M, Karim QA, Heise L.
    J Int AIDS Soc; 2015 Oct; 18(1):20536. PubMed ID: 26700845
    [Abstract] [Full Text] [Related]

  • 45. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women.
    Bentley ME, Morrow KM, Fullem A, Chesney MA, Horton SD, Rosenberg Z, Mayer KH.
    Fam Plann Perspect; 2000 Oct; 32(4):184-8. PubMed ID: 10942354
    [Abstract] [Full Text] [Related]

  • 46. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results.
    Perino A, Consiglio P, Maranto M, De Franciscis P, Marci R, Restivo V, Manzone M, Capra G, Cucinella G, Calagna G.
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6744-6752. PubMed ID: 31378918
    [Abstract] [Full Text] [Related]

  • 47. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.
    Friedland BA, Stoner M, Chau MM, Plagianos MG, Govender S, Morar N, Altini L, Skoler-Karpoff S, Ahmed K, Ramjee G, Monedi C, Maguire R, Lähteenmäki P.
    AIDS Behav; 2016 Nov; 20(11):2565-2577. PubMed ID: 26204987
    [Abstract] [Full Text] [Related]

  • 48. "We have our protector": misperceptions of protection against HIV among participants in a microbicide efficacy trial.
    Mantell JE, Morar NS, Myer L, Ramjee G.
    Am J Public Health; 2006 Jun; 96(6):1073-7. PubMed ID: 16670239
    [Abstract] [Full Text] [Related]

  • 49. Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials.
    Radecki Breitkopf C, Loza M, Vincent K, Moench T, Stanberry LR, Rosenthal SL.
    Sex Transm Dis; 2012 Jan; 39(1):28-31. PubMed ID: 22183842
    [Abstract] [Full Text] [Related]

  • 50. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
    Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgins J, Walsh T, Wan L, Thomas M, Creinin MD, Westhoff C, Schlaff W, Archer DF, Ayers C, Kaunitz A, Das S, Moench TR.
    Obstet Gynecol; 2007 Sep; 110(3):577-86. PubMed ID: 17766603
    [Abstract] [Full Text] [Related]

  • 51. A Pilot Study Measuring the Distribution and Permeability of a Vaginal HIV Microbicide Gel Vehicle Using Magnetic Resonance Imaging, Single Photon Emission Computed Tomography/Computed Tomography, and a Radiolabeled Small Molecule.
    Fuchs EJ, Schwartz JL, Friend DR, Coleman JS, Hendrix CW.
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1109-15. PubMed ID: 26077739
    [Abstract] [Full Text] [Related]

  • 52. Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow.
    Lai BE, Xie YQ, Lavine ML, Szeri AJ, Owen DH, Katz DF.
    J Pharm Sci; 2008 Feb; 97(2):1030-8. PubMed ID: 17724667
    [Abstract] [Full Text] [Related]

  • 53. Potential of vaginal microbicides in HIV control.
    Stone A.
    J R Soc Med; 2004 Mar; 97(3):158. PubMed ID: 14996989
    [No Abstract] [Full Text] [Related]

  • 54. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
    Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, Wilson SS, Porter DD, Lira SA, Keller MJ, Herold BC.
    J Infect Dis; 2007 May 01; 195(9):1332-9. PubMed ID: 17397004
    [Abstract] [Full Text] [Related]

  • 55. Promoting continuous use as a strategy for achieving adherence in a trial of the diaphragm with candidate microbicide.
    Penman-Aguilar A, Swezey T, Turner AN, Bell AJ, Ramiandrisoa FN, Legardy-Williams J, Randrianasolo B, Van Damme K, Dulyx J, Behets F, Jamieson DJ.
    AIDS Educ Prev; 2009 Dec 01; 21(6):512-25. PubMed ID: 20030496
    [Abstract] [Full Text] [Related]

  • 56. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.
    Forbes CJ, McCoy CF, Murphy DJ, Woolfson AD, Moore JP, Evans A, Shattock RJ, Malcolm RK.
    J Pharm Sci; 2014 May 01; 103(5):1422-32. PubMed ID: 24585370
    [Abstract] [Full Text] [Related]

  • 57. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing.
    Braunstein S, van de Wijgert J.
    J Womens Health (Larchmt); 2005 Jun 01; 14(5):424-33. PubMed ID: 15989415
    [Abstract] [Full Text] [Related]

  • 58. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
    Haaland RE, Evans-Strickfaden T, Holder A, Pau CP, McNicholl JM, Chaikummao S, Chonwattana W, Hart CE.
    Antimicrob Agents Chemother; 2012 Jul 01; 56(7):3592-6. PubMed ID: 22508307
    [Abstract] [Full Text] [Related]

  • 59. "Inactive" polymer is active against sexually transmitted diseases.
    Larkin M.
    Lancet; 1999 Jul 31; 354(9176):399. PubMed ID: 10437880
    [No Abstract] [Full Text] [Related]

  • 60. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.
    Giguere R, Carballo-Diéguez A, Ventuneac A, Mabragaña M, Dolezal C, Chen BA, Kahn JA, Zimet GD, McGowan I.
    Cult Health Sex; 2012 Jul 31; 14(2):151-66. PubMed ID: 22084840
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.